hrp0089fc7.3 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2018
Chen Suet Ching
, Dastamani Antonia
, Pintus Donatella
, Yau Daphne
, Aftab Sommayya
, Bath Louise
, Swinburne Craig
, Hunter Lindsey
, Giardini Alessandro
, Christov Georgi
, Senniappan Senthil
, Banerjee Indraneel
, Shaikh Guftar
, Shah Pratik
Objectives: Diazoxide is first line treatment for hypoglycaemia due to hyperinsulinaemic hypoglycaemia (HH). However, the FDA has raised serious concerns regarding diazoxide-induced pulmonary hypertension (PH) in 2015. Although sporadic cases of PH have been reported, no HH cohort has been systematically characterised to understand severity and risk factors for diazoxide-induced PH.Methods: To investigate the onset, progress and associated factors in PH,...